Rova-T (rovalpituzumab tesirine) is an investigational antibody drug conjugate targeting the cancer stem cell-associated target delta-like protein 3 (DLL3). It is also being investigated as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a second-line treatment for extensive-stage small cell lung cancer (SCLC).

Type of Molecule

Biologic

Target

DLL3

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Small Cell Lung Cancer (1L SCLC) New Indication Phase 3
Small Cell Lung Cancer (3L SCLC) New Indication Phase 2
Neuroendocrine Tumors New Indication Phase 1
Small Cell Lung Cancer (2L SCLC) New Indication Phase 2